The ROE as of November 2024 (TTM) for Regeneron Pharmaceuticals, Inc. (REGN) is 16.85%

According to Regeneron Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 16.85%. This represents a change of 301.44% compared to the average of 4.20% of the last 4 quarters.

Regeneron Pharmaceuticals, Inc. (REGN) Historical ROE (quarterly & annually)

How has REGN ROE performed in the past?

The mean historical ROE of Regeneron Pharmaceuticals, Inc. over the last ten years is 22.70%. The current 16.85% ROE has changed -25.76% with respect to the historical average. Over the past ten years (40 quarters), REGN's ROE was at its highest in in the June 2021 quarter at 20.49%. The ROE was at its lowest in in the June 2019 quarter at 1.98%.

Regeneron Pharmaceuticals, Inc. (REGN) ROE by Quarter and Year

Discovering the peaks and valleys of Regeneron Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Regeneron Pharmaceuticals, Inc. (REGN) Average ROE

How has REGN ROE performed in the past?

The current ROE of Regeneron Pharmaceuticals, Inc. (REGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Regeneron Pharmaceuticals, Inc. (REGN) ROE vs. Peers

How is REGN’s ROE compared to its peers?

Regeneron Pharmaceuticals, Inc.’s ROE is greater than CRISPR Therapeutics AG (-13.85%), less than Novo Nordisk A/S (87.50%), less than Sarepta Therapeutics, Inc. (5.17%), greater than Intellia Therapeutics, Inc. (-49.70%), less than Incyte Corporation (0.78%), less than Alnylam Pharmaceuticals, Inc. (323.66%), less than United Therapeutics Corporation (19.22%), greater than Ultragenyx Pharmaceutical Inc. (-266.02%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), less than PTC Therapeutics, Inc. (57.03%), less than Reata Pharmaceuticals, Inc. (19.32%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), less than Krystal Biotech, Inc. (13.36%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than BeiGene, Ltd. (-14.93%), less than BioMarin Pharmaceutical Inc. (7.83%), greater than ImmunoGen, Inc. (-21.97%), greater than Prometheus Biosciences, Inc. (-21.63%), greater than Arrowhead Pharmaceuticals, Inc. (-172.90%), greater than Ionis Pharmaceuticals, Inc. (-115.80%),

Build a custom stock screener for Regeneron Pharmaceuticals, Inc. (REGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regeneron Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Regeneron Pharmaceuticals, Inc. (REGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Regeneron Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.